Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common shares, Euro 0.12 nominal value per share
-
Shares outstanding
-
26,019,256
-
Total 13F shares
-
5,746,005
-
Share change
-
-993,015
-
Total reported value
-
$11,663,321
-
Price per share
-
$2.03
-
Number of holders
-
15
-
Value change
-
-$1,820,220
-
Number of buys
-
8
-
Number of sells
-
11
Institutional Holders of LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) as of Q2 2023
As of 30 Jun 2023,
LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) was held by
15 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
5,746,005 shares.
The largest 10 holders included
Novo Holdings A/S, Redmile Group, LLC, Bruce & Co., Inc., Artal Group S.A., Alpha Wave Global, LP, MILLENNIUM MANAGEMENT LLC, PNC Financial Services Group, Inc., Tower Research Capital LLC (TRC), GEODE CAPITAL MANAGEMENT, LLC, and HRT FINANCIAL LP.
This page lists
14
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.